25 May 2013
Keywords: Multiple Sclerosis, MS, Novartis, Extavia
Article | 17 August 2009
The US Food and Drug Administration (FDA) has approved Extavia (interferon beta-1b), the first in a new planned portfolio ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
17 August 2009
24 May 2013
© 2013 thepharmaletter.com